Myasthenia gravis is an autoimmune disease in which the body’s own antibodies attack the connection between nerves and muscles, called the neuromuscular junction. This disrupts the chemical signaling that tells muscles to contract, producing the hallmark symptom of fluctuating muscle weakness that worsens with activity and improves with rest. About 25 in every 100,000 people have the condition, and understanding the specific ways it disrupts normal signaling is key to understanding why it behaves the way it does.
How the Neuromuscular Junction Normally Works
To understand what goes wrong in myasthenia gravis, it helps to know what the junction does when everything is working. A nerve impulse travels from the spinal cord down a motor neuron until it reaches the nerve terminal at the muscle. When the impulse arrives, the terminal releases a chemical messenger called acetylcholine into the tiny gap (the synaptic cleft) between the nerve and the muscle fiber.
Acetylcholine drifts across the cleft and locks onto receptors on the muscle’s surface. That binding opens channels in the muscle membrane that allow sodium and potassium ions to flow through, creating an electrical shift called the endplate potential. If the endplate potential is large enough, and at a healthy junction it always is, the muscle fiber fires its own electrical impulse and contracts. This whole process happens with a built-in safety margin: the nerve normally releases far more acetylcholine, and the muscle carries far more receptors, than the bare minimum needed to trigger contraction.
Anti-AChR Antibodies: The Most Common Mechanism
About 85% of people with myasthenia gravis produce antibodies that target the acetylcholine receptor (AChR) itself. These antibodies, specifically the IgG1 and IgG3 subtypes, damage the junction through three overlapping mechanisms.
First, some antibodies physically block acetylcholine from binding to the receptor. If the messenger can’t reach its target, the muscle never gets the signal to contract. Second, antibodies can cross-link two adjacent receptors, causing the muscle cell to pull them inside and break them down. This process, called antigenic modulation, steadily reduces the number of available receptors on the muscle surface.
Third, and most destructive, is complement activation. When multiple antibodies bind to clustered receptors on the muscle membrane, they trigger the complement system, a cascade of immune proteins that normally attacks invading pathogens. The cascade assembles a structure called the membrane attack complex, which punches holes directly through the muscle’s postsynaptic membrane. This destroys receptors and voltage-gated channels alike, widens the synaptic cleft, and flattens the normal folds of the muscle surface where receptors are concentrated. Over time, the safety margin erodes. Eventually, even a normal release of acetylcholine can no longer produce an endplate potential strong enough to make the muscle fire. The result is weakness that gets progressively worse with repeated use, as each successive nerve impulse has less and less to work with.
MuSK Antibodies: A Different Path to the Same Problem
About 15% of myasthenia gravis patients test negative for AChR antibodies. Within that group, a significant portion carry antibodies against a protein called muscle-specific kinase (MuSK). MuSK is not a receptor for acetylcholine. Instead, it is part of the machinery that organizes acetylcholine receptors into tight clusters at the junction in the first place.
During normal development, the motor nerve releases a signaling molecule called agrin. Agrin binds to another protein on the muscle surface, LRP4, which in turn activates MuSK. MuSK then works with an intracellular partner called Dok7 to gather acetylcholine receptors and anchor them in dense clusters exactly where the nerve terminal sits. Without this clustering, receptors scatter across the muscle surface, too sparse to generate a reliable signal.
MuSK antibodies are predominantly IgG4, a subtype that does not activate complement. Instead, they directly block the binding between LRP4 and MuSK, cutting off the agrin signaling pathway. Research has shown that even purified antibody fragments are enough to reduce receptor clustering on muscle cells. Interestingly, the smaller population of IgG1-3 antibodies found in MuSK patients works differently: they don’t block LRP4-MuSK binding but still disperse preformed receptor clusters through a separate, agrin-independent mechanism. The end result is the same. Acetylcholine receptors drift apart, the density at the junction drops, and the muscle can no longer respond reliably to nerve signals. MuSK-positive myasthenia gravis tends to produce more prominent weakness in the face, throat, and neck muscles compared to the AChR-positive form.
LRP4 and Agrin Antibodies
A smaller number of patients, particularly those previously classified as “seronegative” (testing negative for both AChR and MuSK antibodies), carry antibodies against LRP4 or agrin. Since LRP4 is the protein that receives the agrin signal and passes it to MuSK, antibodies that block it interrupt the same clustering pathway that MuSK antibodies disrupt. Agrin antibodies prevent the signaling molecule from reaching LRP4 in the first place. Both have been shown to produce myasthenia-like disease in animal models, supporting their role as genuine pathogenic factors rather than bystanders.
The Thymus Gland’s Role
The thymus is a small immune organ behind the breastbone that normally trains T cells to distinguish self from non-self during childhood, then gradually shrinks with age. In myasthenia gravis, the thymus often remains abnormally active and becomes a hub for the autoimmune response.
In early-onset MG, the thymus commonly shows thymic follicular hyperplasia: the gland develops clusters of immune cells called germinal centers, which are essentially antibody factories. Thymic epithelial cells in these patients actually express acetylcholine receptor protein, creating a situation where immune cells are continuously exposed to the very target they shouldn’t be attacking. Heightened interferon signaling and toll-like receptor activation within the gland create a pro-autoimmune environment, driving B cells (with help from T helper cells, particularly the Th1 and Th17 subtypes) to differentiate into plasma cells that churn out AChR antibodies. The thymus essentially becomes a self-contained engine for the disease.
About 10 to 30% of MG patients have a thymoma, a tumor of the thymus gland. Thymomas are more common in men over 50, though they can occur at any age and in either sex. The mechanism is slightly different from hyperplasia, but the result is similar: disrupted immune tolerance and sustained autoantibody production.
Why Weakness Fluctuates and Worsens With Use
One of the most distinctive features of myasthenia gravis is that muscles get weaker the more you use them and recover partially with rest. This pattern is a direct consequence of the reduced safety margin at the junction. In a healthy junction, every nerve impulse releases enough acetylcholine to generate an endplate potential well above the threshold needed for contraction. In a myasthenic junction, with fewer receptors and a damaged postsynaptic membrane, the endplate potential barely clears the threshold, or sometimes doesn’t clear it at all.
With repeated stimulation, the amount of acetylcholine released per impulse naturally declines slightly, a normal phenomenon that healthy junctions easily absorb. A damaged junction cannot. After several contractions, the endplate potential drops below threshold, individual muscle fibers stop responding, and the muscle as a whole becomes noticeably weaker. Rest allows acetylcholine stores to replenish and the few remaining receptors to recover, temporarily restoring function.
Myasthenic Crisis and Respiratory Failure
When the disease flares severely, it can progress to myasthenic crisis: weakness of the breathing muscles serious enough to require ventilatory support. The diaphragm and intercostal muscles that drive breathing are skeletal muscles, subject to the same neuromuscular junction dysfunction as any other. In AChR-positive MG, the intercostal and accessory muscles tend to weaken first, followed by the diaphragm.
Respiratory failure in crisis isn’t limited to the muscles of breathing. Weakness of the upper airway and bulbar muscles (those controlling the throat, tongue, and palate) can cause the airway to collapse or the tongue to obstruct airflow. This forces already fatigued respiratory muscles to work harder against a partially closed airway, accelerating the spiral. Weak coughing further compounds the problem by preventing adequate clearing of secretions. Infections, surgery, certain medications, and emotional stress are common triggers.
Medications That Can Worsen the Junction
Because the neuromuscular junction is already compromised, certain drugs can tip the balance further. Aminoglycoside antibiotics (such as gentamicin and tobramycin) and clindamycin both potentiate neuromuscular blockade. Magnesium, whether given intravenously or taken in high doses, enhances the same effect. Calcium channel blockers, lithium, and certain anti-arrhythmic drugs like procainamide and quinidine also increase sensitivity. People with myasthenia gravis are dramatically more sensitive to neuromuscular blocking agents used during anesthesia, which is why surgical teams need to know about the diagnosis in advance.
Transient Neonatal Myasthenia Gravis
Babies born to mothers with MG can develop a temporary form of the disease. IgG antibodies cross the placenta throughout pregnancy, with transfer ramping up significantly during the second and third trimesters. After week 36, there is a sharp increase in transfer, and by birth, the total IgG level in cord blood typically exceeds the mother’s level by 20 to 30%. For AChR antibodies specifically, the newborn’s titer can surpass the mother’s by more than 300%.
These borrowed antibodies attack the baby’s neuromuscular junctions just as they do the mother’s, causing weak cry, poor feeding, and reduced muscle tone. The condition is self-limiting because the baby’s body does not produce the antibodies itself. Symptoms last an average of two to three weeks, with 90% of affected infants fully recovering within two months and the remainder resolving within four months. This timeline matches the expected clearance rate of IgG, which has a half-life of roughly three weeks.